Sun Pharma aiming to spend 7-8% of sales on R&D in current fiscal

29 Aug 2023 Evaluate

Sun Pharmaceutical Industries is aiming to spend 7-8 per cent of its sales in the current fiscal on research and development activities as it looks to further strengthen its product portfolio across therapeutic segments.

The Mumbai-based drug major spent about Rs 2,400 crore on R&D in 2022-23, which accounted for about 5.5 per cent of the sales as it continued to invest product pipeline for both global generics and specialty businesses.

Sun Pharmaceutical Industries is the world's fourth largest specialty generic pharmaceutical company and India's top pharmaceutical company.

Sun Pharma Inds. Share Price

1826.10 -11.20 (-0.61%)
09-Jan-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1826.10
Dr. Reddys Lab 1371.60
Cipla 1488.15
Lupin 2251.80
Zydus Lifesciences 1009.40
View more..
© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.